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1. Introduction 
Idiopathic Parkinson’s disease (PD) is a neurodegenerative disorder of the central nervous 
system that affects 1.5 million of individuals in the United States (American Parkinson 
Disease Association, 2011). Although its etiology is still unclear, the degeneration of the 
dopaminergic neurons in the substantia nigra stands out as the prominent pathological 
feature (Hauser, 2010). It seems that the balance between the dopamine, acetylcholine and 
glutamate neurotransmitters is compromised in PD, which may play a role in the 
subcortical-frontal behaviour impairment (Dubois et al., 1990). Other classical features of PD 
include the presence of Lewy bodies in the brainstem pigmented neurons, typical 
characteristics of the ǂ-synucloeopathy in PD (Jellinger, 2003, 2011), and neuronal losses in 
the locus coeruleus (Aarsland et al., 2009). 
In addition, the incidence and prevalence of cognitive impairment and dementia, as well 
as the relative risk for dementia, are higher in PD than in healthy elderly (Aarsland et al., 
2001; Aarsland et al., 2005; de Lau et al., 2005;); this is thus an important problem. Some 
clinical and demographical risk factors for cognitive impairment and dementia in PD 
(PDD) have consistently been reported. More severe motor features such as gait 
disturbance, rigidity and postural instability tend to predict a faster cognitive decline and 
thus, an earlier dementia diagnosis (Aarsland et al., 2005; Aarsland & Kurz, 2010). The 
association of extrapyramidal signs with cognitive impairment supports the hypothesis of 
a role for PD subcortical pathology in the development of dementia (Levy et al., 2002; 
Bancher et al., 1993). Older age, disease duration and older age at onset were also 
identified as prominent risk factors for cognitive impairment in PD (Aarsland et al., 2001; 
Aarsland & Kurz, 2010; Hughes et al., 2000). Other potential features likely to predict 
cognitive impairment and PDD include visual hallucinations and genetic factors 
(Aarsland et al., 2010). However, these risk factors and their impact on cognition will not 
be directly reviewed in the present chapter, as they are considered to be respectively 
neuropsychiatric and genetic risk factors. 
As in Alzheimer’s disease (AD) (Petersen, 2004), Mild Cognitive Impairment (MCI) is 
another potential predictive factor for PDD (Aarsland et al., 2010). In this context, a 
significant number of non-demented PD patients present with MCI (Aarsland et al., 2010; 
www.intechopen.com
 Neurodegeneration 
 
324 
Ebmeier et al., 1991; Muslimovic et al., 2005). Some cognitive deficits, notably on tests of 
memory and executive functions predicted a shorter evolution toward PDD in some studies 
(Levy et al., 2002; Janvin et al., 2005). Poor performances on tests involving posterior cortical 
areas such as the semantic fluency test and the copy of a figure test would be the most 
important predictors of cognitive decline according to some authors (William-Grays et al., 
2007). However, the profile of cognitive impairment is heterogeneous, some patients 
presenting with memory impairment while others show more language, executive and 
visuospatial impairments (Elgh et al., 2009; Janvin et al., 2005; Uc et al., 2009). Identifying 
factors contributing to cognitive deterioration is a noteworthy goal because a diminution in 
quality of life and an augmentation of mortality are associated with cognitive impairment 
and dementia in PD. Vascular risk factors (VRF) are among those factors. Several studies 
support the contribution of VRF in elderly adults in the development of vascular dementia 
and of Alzheimer’s disease (Gorelick et al., 2011, for a review; Wiederkehr et al., 2009). 
Indeed, in the statement for healthcare professionals from the American Heart 
Association/American Stroke Association, blood pressure, hyperglycemia/diabetes, 
hypercholesterolemia, stroke, heart disease, alcohol intake and smoking were some of the 
VRF pointed out as being involved in vascular cognitive impairment, a possible prodromal 
phase of dementia (Gorelick et al., 2011). 
However, there is a controversy regarding the occurrence and impact of the VRF on 
cognition and on the clinical evolution in PD and there is a lack of systematic review on the 
topic (Aarsland & Kurz, 2010; Korczin, 2010). Only one review was found but it was strictly 
investigating the possible link between elevated () homocysteinemia (Hcy), L-dopa 
treatment and cognitive dysfunction and dementia in PD but it did not question the possible 
involvement of other VRF in cognitive impairment in PD (Zoccolella et al., 2010). This article 
reviewed 16 studies on Hcy and cognitive impairment, dementia and neurodegenerative 
markers in PD (Zoccolella et al., 2010). However, 5 of the studies were only available as 
abstracts of conference presentations. The current review will thus use more stringent 
inclusion criteria for articles and will update as well as build upon the data of Zoccolella et 
al. (2010) regarding hyperhomocysteinemia as a possible VRF for cognitive impairment and 
dementia in PD. The present work will also review the possible involvement of other VRF 
such as hypertension (HT), type 2 diabetes mellitus (DM), heart disease (HD), 
hypercholesterolemia (HCL), stroke history (SH) /transient ischemic attacks (TIA), alcohol 
intake (ALC) and smoking (SMO) in the development of cognitive impairment and 
dementia in PD.  
In summary, there is currently no consensus regarding the presence of VRF and their impact 
on cognition in PD. Therefore, the first objective of the current chapter is to perform a critical 
literature review on the cognitive profile of patients with PD and VRF in order to clarify this 
issue. The second objective is to investigate the possible biological mechanisms underlying 
the presence of VRF and cognitive dysfunctions in PD. Finally, some recommendations will 
be made to improve future research in this area.  
2. Method 
A search in MEDLINE/PubMed, PsycINFO and AgeLine (EBSCO) databases was 
conducted using the following keywords: (1) “Parkinson” AND “cognition/cognitive” AND 
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“vascular risk factors”, (2) “Parkinson” AND “cognition” AND “smoking/tobacco 
smoking/cigarette” OR “hypertension” OR “hypercholesterolemia” OR “diabetes/diabetes 
mellitus” OR “homocysteine/hyperhomocysteinemia” OR “alcool” OR “heart disease. The 
search included articles published from 1990 to May 31st, 2011. A manual search in the 
references of the selected articles was also performed as a second step to identify other 
pertinent publications. The selected articles had to meet the following inclusion criteria: 1) 
articles had to be published in English or French in order to be reviewed. 2) While 
longitudinal controlled studies were prioritized, cross-sectional studies with controls 
and/or using between-patient or within-patient comparisons were also considered. 3) 
Studies had to not only report VRF in PD, but also had to assess cognition using at least one 
standardized cognitive measure; and the authors had to report the results of the cognitive 
assessment. The studies were excluded if they were only case reports. The articles were 
independently reviewed by the two co-authors and final data were registered following a 
consensus meeting. 
3. Results 
3.1 Search results 
Eighteen articles published from 1990 to 2010 met the inclusion criteria of the review (Alves 
et al., 2004; Barone et al., 2008; Camicioli et al., 2009; Hassin-Baer et al., 2006; Haugarvoll et 
al., 2005; Kandiah et al., 2009; Levy et al., 2002; Marder et al., 1990; Matteau et al., 2010; 
O’Suilleabhain et al., 2006; Ozer et al., 2006; Rektor et al., 2009; Religa et al., 2006; Rodriguez-
Oroz et al., 2009; Slawek et al., 2008; Weisskopf et al., 2007; Zoccolella et al., 2009; Zoccolella 
et al., 2005). Sixteen articles were rejected because: 5 were only abstracts (Antonini et al., 
2006; Litvinenko et al., 2005; Menendez et al., 2007; Shin & Sohn, 2006; Stathis et al., 2006), 6 
didn’t report the results of the cognitive assessment or didn’t assess cognition using at least 
one standardized cognitive measure (Blandini et al., 2001; Ebmeier et al., 1990; Kuhn et al., 
1998; Muller et al., 1999; Nakaso et al., 2006; Yasui et al., 2000; ) and 5 didn’t assess the 
effects of vascular risk factors (Aarsland et al., 2004; de Lau et al., 2005; Hughes et al., 1992; 
Locascio et al., 2003; Papapetropoulos et al., 2006).  
3.2 Design and sample size of the studies 
Table 1 summarizes the study design and participant’s characteristics in the 18 selected 
studies. Only 1 study had a randomized double-blind placebo-controlled design (R-DB-PC) 
since it was a clinical trial on rivastigmine, 1 study had a longitudinal (LON) case-control 
(CC) design (follow-up of 8 years), 4 studies were longitudinal with between-patient 
comparisons (BPC) with mean follow-ups ranging from 2.0 to 4.0 years, 6 studies had a case-
controlled design, 5 studies were cross-sectional (CS) with between-patient comparisons, 
and 1 study was cross-sectional using within-patient comparisons (WPC). 
The number of PD patients included in the studies ranged from 35 to 342, whereas the 
number of healthy controls (when applicable, n=7 studies) ranged from 28 to 1144. One 
study (Alves et al., 2004) had 2 control groups: 100 healthy controls and 100 patients with 
only diabetes mellitus. The mean (SD) sample size for the 18 selected studies is 124.7 (87.5) 
PD patients and 229.4 (405.8) healthy controls (HC). However, 9 studies (50%) had <100 PD 
patients in their samples; and these small sample sizes reduce statistical power.  
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The PD patient groups were often divided into comparison subgroups with VRF/no-VRF 
(n=7 studies), dementia/no dementia (n=3 studies), normal cognitive function/mild 
cognitive impairment/dementia (n=3 studies), cognitive decline/no cognitive decline (n=1 
study) and levodopa treated/untreated (n=1 study).  
3.3 Participants characteristics 
The mean age of PD patients in the 18 studies varied from 59.0 to 75.5 years old. However, 
PD patients were usually older than 65 years old (11/18 studies). Regarding the gender of 
patients, only one study didn’t report the gender of the subjects (Religa et al., 2006). In most 
studies (n=15 studies), the male/female ratio was equal. However, one study had a 
significant greater number of male patients in the VRF compared to the no-VRF group 
(Haugarvoll et al., 2005) and another study had a significantly greater number of male 
patients in the two elevated homocysteine groups (Hassin-Baer et al., 2006). 
Out of the 18 selected articles, only 7 reported the level of education of the participants in 
mean years of schooling. Although one study reported education as the percentage of 
patients having completed primary school (Rodriguez-Oroz et al., 2009) and another study 
as the percentage of patients having completed an academic degree (Weisskopf et al., 2007), 
11 studies didn’t report the education level of the participants at all. Among the 7 studies 
reporting education as the number of years attending school, the mean years of education 
varied from 5.7 to 15.2 years. Nevertheless, PD patients had at least 10 years of education in 
4/7 studies that reported the education level. Therefore, most patients were well-educated. 
PD patients were recruited in movement disorder centers/clinics (MDC) (9 studies), general 
hospitals (HOS) (3 studies), community (COM) (2 studies), movement disorder database 
(MDB) (2 studies) and in multiple centers from different North-American and European 
countries (MC) (1 study). Only one study didn’t report clearly the recruitment location. 
Healthy controls (HC), when applicable, were recruited in general hospitals in 3 studies and 
in the community in 3 studies while the recruitment location was not clearly stated in 1 
study. 
Mean disease duration in PD patients (at baseline when applicable) varied from less than 2 
years to 14.7 years. Only one study didn’t report the disease duration directly, but specified 
that it was less than 2 years, because the study focused on newly diagnosed patients 
(Kandiah et al., 2009). 
The Hoehn & Yahr stage (H&Y) is a simple scale to globally assess PD severity (Hoehn & 
Yahr, 1967): stage 0= no signs of disease; stage 1= very mild symptoms on only one side of 
the body; stage 1.5= symptoms on only one side of the body with axial involvement; stage 
2= symptoms on both sides without balance impairment; stage 2.5= mild symptoms on both 
sides with recovery on pull test; stage 3= mild to moderate symptoms and potential postural 
instability with maintenance of independence; stage 4= severe symptoms (patient is severely 
debilitated and needs assistance but can walk and stand alone); and stage 5=very severe 
symptoms confining the patients to a wheelchair or a bed unless assisted.  
Ten of the 18 selected articles reported the H&Y stage of the PD patients, and it ranged 
between 2.1 and 3.9. However, one study reported only that patients were equal to or below 
stage 3.0 (Religa et al., 2006). Another study (Barone et al., 2008) reported H&Y stages with 
the percentage of patients in each stage, including 54/342 patients in the 4.0-5.0 range, 
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which was rare in the studies reviewed herein. Nonetheless, the mean H&Y stage was below 
3.0 in 7 out of 9 studies; thus most studies included patients in the early stages of PD. 
The Unified Parkinson’s disease Rating Scale (UPDRS) is a tool designed to assess different 
clinical aspects of patients in the PD course (Fahn et al., 1987). It allows a comprehensive 
coverage of motor symptoms and was proved to be valid and reliable (Movement Disorder 
Society Task Force on Rating Scales for Parkinson's Disease, 2003). Higher scores are 
associated with greater disability. Section I (maximum=16 points) assesses mentation, 
behaviour and mood (4 items). Section II (maximum=52 points) evaluates the activities of 
daily living (ADL) with 13 items. Section III (maximum=108 points) consists in a motor 
examination (14 items). Section IV evaluates clinical signs. A total of 13/18 studies reported 
the UPDRS score of patients. Two studies reported the score for sections I-IV (ranging from 
22.9 to 50.9) and only one study reported the total score (I-V). However, most studies (n=10) 
only reported the motor examination (section III) score. Motor scores ranged from 17.3 to 
48.1 in these studies and most of them (n=8 out of 10) had PD patients with a score of 35.0 
and lower. In other words, in most studies, patients had mild to moderate motor symptoms. 
Four studies assessed the UPDRS when patients were “ON”, whenever ON-OFF 
fluctuations were present, while only one study assessed them in the OFF state, and 8 
studies didn’t specify the procedure.  
Table 2 presents the three sets of PD diagnostic criteria that were used in the 18 articles. The 
United Kingdom Parkinson’s Disease Society Brain Research Centre (UKPDSBRC) criteria 
(Gibb et al., 1988; Hughes et al., 1992) were the most commonly used (n=9 studies), followed 
by the National Institute of Neurological Disorders and Stroke (NINDS) criteria (Gelb et al., 
1999) (n=3 studies) and the Norwegian criteria of Larsen et al. (1994) (n=2 studies). The 
diagnosis was made only using the clinical impression of neurologists in one study 
(Weisskopf et al., 2007) and 3 studies didn’t specify the diagnostic criteria used.  
3.4 Vascular risk factors 
Table 3 summarizes the frequency of the different vascular risk factors in the selected 
studies, their measures and the medication taken by the participants.  
3.4.1 Hyperhomocysteinemia (↑Hcy) 
Homocysteine (Hcy) is a sulfur-containing amino acid found in blood plasma and naturally 
biosynthesized as an intermediate product from the demethylation of the amino acid 
methionine (Reutens & Sachdev, 2002; Stanger et al., 2003). Hcy is metabolized in three 
distinct pathways (Mattson & Shea, 2003). Two pathways involve remethylation: the first 
(via the enzyme betaine-homocysteine methyltransferase) occurs in the liver and kidneys 
while the second (via the enzyme methionine synthase), catalyzed by 
methylentetrahydrofolate reductase (MTHFR), occurs in all human tissue and requires 
vitamin B12 and folate as cofactors. A third metabolic pathway involves transsulfuration 
(via the enzymes cystathionine-ǃ-synthase (CǃS) and Ǆ-cystathionase) with vitamin B6 as a 
cofactor. (Mattson & Shea, 2003; Reutens & Sachdev, 2002).  
The American Society of Human Genetics and the American College of Medical Genetics 
(ASHG/ACMG, 1998) define normal blood plasma level of Hcy as ranging from 5.0 to 15.0 
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μmol/L and hyperhomocysteinemia as a fasting total plasma Hcy level of >15.0 μmol/L. 
Plasma Hcy level increases with age and is higher in men than in women. The effect of age 
is partly explained by the diminution of renal function with increasing age (Stanger et al., 
2003). 
Hyperhomocysteinemia(ŃHcy) is due to multiple etiologies. Genetic abnormalities in genes 
encoding for enzymes involved in Hcy metabolism could partially explain an increase in 
Hcy concentration. Carriers of a thermolabile variant of MTHFR at nucleotide position 667 
(MTHFR 677CńT) present a reduced enzymatic activity of MTHFR by approximately 70%, 
which leads to an increased level of blood plasma Hcy (Stanger et al., 2003). Vitamin 
deficiencies are probably the main factors of acquired ŃHcy and can be the consequences of 
insufficient dietary intake, reduced absorption, increased consumption and drug 
interactions (Stanger et al., 2003). Some other relevant acquired causes of ŃHcy include older 
age, renal failure (impaired remethylation), hypothyroidism (enzyme induction), alcohol 
intake (interference with B6, B12 and folate + enzyme inhibition) and cigarette smoking 
(interference with B6, B12 and folate + redox) (Finkelstein, 1998; Reutens & Sachdev, 2002; 
Stanger et al., 2003).  
Levodopa (L-dopa) intake in PD was associated with Hcy blood and plasma levels (Kuhn et 
al., 1998; Müller et al., 1999; Rogers et al., 2003; Yasui et al., 2000). Levodopa is a substrate for 
S-adenosyl methionine (SAM)-dependent methylation. In fact, levodopa O-methylation to 3-
O-methyldopa by cathecol-O-methyltransferase (COMT) constitutes a main metabolic 
pathway (Müller et al., 2002). COMT converts S-adenosylmethionine to S-
adenosylhomocysteine which will eventually become Hcy. Therefore, ŃHcy in PD is most 
likely the consequence of S-adenosylhomocysteine formation during levodopa breakdown 
(Müller et al., 2001, 2002).  
Some studies also support a genetic role in ŃHcy in PD: blood plasma levels are elevated in 
levodopa-treated patients homozygous for the MTHFR C667T mutation ( Kuhn et al., 2001; 
Todorovic et al., 2006; Yasui et al., 2000). Hcy has also been involved in multiple biological 
mechanisms and notably as a neurotoxin contributing to neurodegeneration. Hcy is linked 
to increased oxidative stress, excitotoxicity, promotion of cellular apoptosis and the 
promotion of the pathophysiological processes of Alzheimer’s like disease (Sachdev, 2005). 
A total of 9 studies reported total Hcy levels in the PD groups and the number of PD 
patients with ŃHcy ranged from 17 to 247. Only two studies didn’t report the number of 
hyperhomocysteinemic patients. Nevertheless, the number of PD patients with ŃHcy was 
below 31 in 5/7 studies, which are rather small groups. 
3.4.2 Smoking (SMO) 
Smoking is associated with cardiovascular disease and is potentially a VRF for cognitive 
impairment because its pathological mechanisms are known to increase oxidative stress, to 
increase inflammation and to promote thrombosis and atherosclerotic processes (Ambrose 
& Barua, 2004; Swan & Lessov-Schlaggar, 2007). Cigarette smoking reduces blood 
circulation by narrowing the arteries and thus, puts tobacco users at higher risk of 
developing peripheral vascular disease. Light and heavy smoking also results in a 
detrimental effect on endothelial vasoregulatory activity, thus leading to increased 
cardiovascular risk (Barua et al., 2002). 
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A total of 9 studies reported smoking in the PD patients. The number of PD patients who 
ever smoked (past + current smokers) varied from 10 to 78. However, the number of 
smokers is unknown in 2/9 studies. Only one study included smoking HC (n=49) (Alves et 
al., 2004). The distinction between past smokers and current smokers is clear in only 2 
studies. 
3.4.3 Diabetes Mellitus – Type 2 Diabetes (DM) 
Type 2 diabetes mellitus (DM) is a metabolic disorder characterized by high blood glucose 
in the context of insulin resistance and insulin deficiency. Hyperglycemia is associated with 
functional changes in cerebral blood flow (Cosentino et al., 2009). Although the mechanism 
underlying the link between DM and cognitive impairment and dementia is still not well 
understood, it likely involves several inter-related processes. DM is thus a risk factor for 
stroke (Stegmayr & Asplund, 1995) and it is also assumed to be a risk factor for vascular 
dementia (Skoog, 1994; Tatemichi et al., 1993). Some biological links have also been 
described between DM and AD, such as indications of advanced glycation end-products 
(AGE) and increased AGE receptor expression in brains of patients with AD. As AGEs are 
known to be involved in DM complications, diabetes might thus influence AD brain 
pathology (Yan et al., 1997), and AD pathogenesis can be present in PD and PDD.  
A total of 8 studies reported DM in PD and the number of PD patients with DM varied from 
3 to 16. Out of these, the number of PD patients with DM is unknown in 3/8 studies. 
Another study (Alves et al., 2004) had 100 control participants with DM but not with PD. 
3.4.4 Arterial Hypertension (HT) 
A normal blood pressure (nBP) is required to maintain cognitive functioning, because it 
contributes to adequate cerebral perfusion. Hypertension (HT) is not only an important risk 
factor for strokes and heart disease; it is also an immediate risk factor for cognitive 
impairment and vascular dementia (Breteler, 2000). Individuals suffering from HT have 
stiffer artery walls and increased blood vessel resistance. This requires the heart to work 
harder in order to pump the blood, thus increasing the pressure of the blood leaving the 
heart and consequently increasing the risk of cerebrovascular ischemic damage (Chobanian 
et al., 2003). Blood pressure is often classified in different stages. According to the American 
Heart Association (Chobanian et al., 2003), nBP is defined as systolic pressure (SP) of 90-119 
mmHg and diastolic pressure (DP) of 60-79 mmHg. Prehypertension is characterized by 
SP=120-139 mmHg and DP=80-89 mmHg, stage 1 hypertension by SP=140-159 mmHg and 
DP=90-99 mmHg, and stage 2 hypertension as SP ≥160 mmHg and DP ≥100 mmHg 
(Chobanian et al., 2003).  
A total of 10 studies reported arterial HT in PD. The number of PD patients with HT varied 
from 14 to 68, and was generally below or equal to 40 patients (n=6 studies). However, 3/10 
studies didn’t report the exact number of PD patients with HT.  
3.4.5 Heart Diseases (HD) 
Commonly included in the heart disease (HD) category are coronary heart disease, heart 
failure and atrial fibrillation (AF). Coronary heart disease consists in the narrowing by 
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atherosclerosis of the blood vessels that supply blood, nutrients and oxygen to the heart. 
Therefore, the consequent limitation of the blood flow to the heart muscle is responsible for 
ischemia. Coronary heart disease is one of the most common causes of heart failure 
(American Accreditation Health Care Commission (A.D.A.M.) Medical Encyclopedia, 2011). 
Heart failure is a condition in which the heart can no longer pump enough blood to every 
body part (Jessup et al., 2009). Systolic heart failure is characterized by insufficient blood 
ejection out of the heart while diastolic heart failure consists in heart muscles harder to fill 
up with blood. AF consists in a problem with the contraction rhythm of the atria that causes 
the blood to be ineffectively pumped to the ventricles. Hence, the arrhythmia is responsible 
for irregular blood flow throughout the whole body. AF is also a risk factor for heart failure 
(National Collaborating Centre for Chronic Conditions, 2006). Moreover, some studies 
reported that atrial fibrillation is associated with a higher risk for conversion to dementia in 
MCI non-PD patients (Ravaglia et al., 2006). 
A total of 6 studies reported heart diseases in PD. The number of PD patients with HD 
ranged from 14 to 28, but the number is unknown in 2/6 studies. Four out of 6 studies 
included coronary heart disease in the HD category with n of PD patients varying from 9 
to 17 (unknown in 2 studies). Atrial fibrillation (AF) and heart failure were reported in 2 
studies: in one of these studies, only one patient was affected by AF, and 9 patients had 
heart failure, whereas the numbers for AF and heart failure are unknown in the other 
study.  
3.4.6 Hypercholesterolemia (HCL) 
Hypercholesterolemia (HCL) is a form of dyslipidemia defined as an abnormal amount of 
lipids in the blood, and is an established VRF for dementia (Luschinger et al., 2005). The 
mechanisms underlying the role of HCL in the development of dementia are not clearly 
understood. However, there is evidence that cholesterol alters the degradation of amyloid 
precursor protein and shows an effect on amyloid fibril formation, which may play a role in 
the pathogenesis of AD (Sponne et al., 2004). Amyloid abnormalities were described in the 
brains of PD patients with cognitive impairment (Braak & Braak, 1990) as well as of PDD 
patients (Nobili et al., 2011). Therefore, HCL could be a VRF for cognitive impairment and 
PDD, via its possible contribution to amyloid aggregation. 
Three studies reported HCL in PD patients but only 2 studies mentioned the number of 
patients presenting with this condition (n=16 and 34).  
3.4.7 Stroke History (SH) / Transient Ischemic Attacks (TIA) 
The link between stroke and cognitive impairment and dementia is very well known (Chui 
et al., 1992; Roman et al., 1993). A stroke in any higher processing cerebral area will 
inevitably cause cognitive dysfunctions. One of the strongest predictors of cognitive decline 
after an initial stroke is the occurrence of a second stroke (Gorelick et al., 2011). 
Only 4 studies reported a stroke history (SH) or transient ischemic attacks (TIA) and the 
number of patients with this VRF varied from 2 to 5 in 3 studies; one study didn’t indicate 
the number of patients with this VRF. 
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3.4.8 Alcohol (ALC) 
Observational studies have shown that alcohol consumption might be related to Hcy in a J-
shaped fashion: chronic consumers (alcoholics) have very high levels of Hcy and moderate 
alcohol consumers (≤ 4 glasses/day) have lower Hcy levels as compared to non-drinkers 
(De Bree et al., 2001). Therefore the rationale for considering alcohol as VRF for cognitive 
impairment in PD might be partly explained by its deleterious effect on Hcy levels. It also 
lowers vitamin B12 and folate levels (Gibson et al., 2008).  
Only 3 studies reported alcohol intake and the number of PD patients consuming alcohol 
was unknown in one study, n=7 in another, and another study distinguished 44 former and 
29 current consumers.  
3.5 Medication 
L-Dopa was the most common medication taken by PD patients (n=14 studies) and doses 
varied from 326.7 to 1028.0 mg/day with a mean of 589 mg/day. Other medications 
included dopamine agonists (n=5 studies) and anticholinergics (n=3 studies). Only one 
study reported the use of antipsychotic and antidepressant drugs. Thus the groups included 
in this review were generally neither depressed nor psychotic. Only 3/18 studies didn’t 
report the medication taken by the PD patients. 
3.6 Cognition and VRF 
Results and tests of the neuropsychological assessment in the 18 studies are illustrated in 
Table 4. Cognitive tests are grouped under specific cognitive domains and are presented 
below, starting from the most prevalent to the least prevalent in the studies. 
Global cognitive function was assessed in 17/18 studies and the most administered tests 
were the Mini-Mental State Examination (MMSE) (n=15 studies) and the Dementia Rating 
Scale (DRS) (n=3 studies). Intelligence (global cognitive function) was also evaluated in one 
study using the Wechsler-Bellevue Intelligence Scale (WBIS). However, no association with 
the VRF could be made, since the authors used the WBIS only to assess the premorbid 
cognitive state of the patients. The other tests assessing global cognitive function were only 
used once (see Table 4). 
3.6.1 Association between VRF and risk for dementia (global measure of dementia) 
Six studies investigated the association between VRF and the risk of incident dementia in 
PD. Dementia was generally assessed using MMSE in 5/6 studies (see Table 4). Zoccolella et 
al. (2009) found that Hcy levels were significantly higher in the PDD group compared to the 
PD group without dementia. The risk for dementia in the Hcy group was significantly 
higher than in the <12.4 μmol/L (normal Hcy) group. A multivariate logistic regression 
showed that Hcy was associated with presence of dementia. However, Rodriguez-Oroz et 
al. (2009) found that Hcy levels didn’t predict the cognitive status of PD patients. 
Levy et al. (2006) found that current and ever smoking were associated with a higher risk for 
PDD, but past smoking was not. They also reported that smokers who stopped smoking less 
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than 8 years before PD onset had a higher risk for PDD. However, pack-years of smoking 
and smoking duration weren’t associated with a higher risk for PDD. 
Zoccolella et al. (2009) found that HT was significantly more frequent in the PDD group 
compared to the PD group without dementia. Haugarvoll et al. (2005) found that PDD had 
more heart failure than patients without dementia after a 4-year follow-up. Slawek et al. 
(2008) demonstrated that HD was significantly more prevalent in the PDD group compared 
to the cognitively normal PD patients, though it was only a weak predictive factor for 
dementia.  
However, results of various regression analyses did not find heart failure, coronary HD, AF, 
stroke, TIA, HT, DM, HCL, ALC and SMO to be predictive of dementia (Haugervoll et al., 
2005; Levy et al., 2006; Marder et al., 1990; Slawek et al., 2008; Zoccolella et al., 2009). 
3.6.2 Association between VRF and a score of global cognition 
Hcy in PD patients was associated with worse global cognition per the MMSE compared to 
patients with normal Hcy in only 2 studies (Religa et al., 2006; Zoccolella et al., 2005), but 
there was no difference between L-dopa-treated and non-L-dopa treated patients (Religa et 
al., 2006).  
Six studies (Barone et al., 2008-at baseline only); Camicioli et al., 2009; Hassin-Baer et al., 
2006; O’Suilleabhain et al., 2004, 2006; Ozer et al., 2006; Rodriguez-Oroz et al., 2009) found 
no association between Hcy and worse global cognition as measured by the MMSE (n=5 
studies), the ADAS-Cog (n=1), the BDS (n=1), the DRS (n=1) and the STMS (n=1 study). 
However, the R-DB-PC study of Barone et al. (2008) found that ŃHcy-rivastigmine-treated 
patients significantly improved their performance after 24 weeks on the ADAS-Cog and the 
MMSE compared to ŃHcy–placebo-treated-patients. This improvement wasn’t present in the 
normal/low Hcy groups, suggesting a relationship between cognition, ŃHcy and successful 
treatment with a cholinesterase inhibitor (rivastigmine). Interestingly, O’Suilleabhain et al. 
(2004, 2006) only found a significant difference between the PD group with Hcy ≥14 μmol/L 
compared to the  PD with Hcy <14 μmol/L when they pooled together the results of all 
neuropsychological tests (14). However, Hcy at baseline was not associated with a greater 
decline on the pooled scores 2 years later. 
Two studies reported some kind of relationship between smoking in PD patients and poor 
cognition. Weisskopf et al. (2007) found that smoking was associated with worst global 
cognition (per the TICS), and the risk for cognitive impairment was significantly higher for 
current smokers compared to never smokers. In the study of Matteau et al. (2010), patients 
with VRF (smoking in the past 10 years, myocardial infarct, stroke, DM and HT) performed 
significantly more poorly on the MMSE compared with no-VRF patients, independently of 
disease duration. In this particular study, the most prevalent VRF (in 66% of PD patients) 
was a history of smoking in the past 10 years, suggesting a possible relationship between 
smoking and global cognition in PD. 
However, smoking and global cognitive function were not associated together in 4 studies 
with cross-sectional analyses and at 4 and 8-year follow-ups in one study. In addition, there 
was no difference between PD non-smokers, all smokers and heavy smokers (20 pack-years 
and more) on cognition (Alves et al., 2004; Marder et al., 1990). In another study, the MMSE 
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score of PD patients was associated with an increase of intimomedial thickness (an indicator 
of large vessel impairment) but not with smoking, HT, DM, ischemic HD and stroke (Rektor 
et al., 2009). 
Finally, Slawek et al. (2008) found that coronary HD was associated with a lower score on 
the MMSE, whereas Kandiah et al. (2009) found that diabetes mellitus didn’t predict 
cognitive decline as measured by the MMSE.  
3.6.3 Episodic memory  
Episodic memory was assessed in 10 studies and the most administered tests were the 
Benton Visual Retention Test (BVRT) (n=2 studies), the Rey Auditory Verbal Learning Test 
(RAVLT) (n=2 studies) and memory subtests of the Wechsler Memory Scale (WMS) (n=2 
studies). All other tests assessing episodic memory were only used once (see Table 4).  
Ozer et al. (2006) found significant lower scores on the Sozel Bellek Surecleri Test (SBST) -
delayed recall (verbal memory) in the PD group with Hcy ≥14 μmol/L compared to PD with 
Hcy <14 μmol/L, but not on the visual memory subtest of the WMS. In the study of 
O’Suilleabhain et al. (2004, 2006), PD with Hcy ≥14 μmol/L significantly declined on the 
Rey-Osterrieth-Complex-Figure (ROCF)-immediate recall at 2-year follow-up, whereas PD 
with Hcy <14 μmol/L did not. However, the baseline performances of these patients were 
comparable on episodic memory measures.  
Two studies assessing episodic memory did not find significant differences or correlations 
between patients Hcy levels and measures of episodic memory (Hassin-Baer et al., 2006; 
Rodriguez-Oroz et al., 2009). 
Coronary heart disease was associated with a lower score on the RAVLT, a measure of 
verbal episodic memory (Slawek et al. 2008) whereas an increased intimomedial thickness 
and pulsatility index (an indicator of small vessel impairment) were correlated with the 
WMS-III- Recognition-word list II (Rektor et al., 2009). 
There was no association between the presence of SMO (Rektor et al., 2009; Slawek et al., 
2008; Weisskopf et al., 2007), HT, DM, ischemic heart disease, HCL, stroke, and alcohol 
intake and measures of episodic memory (Rektor et al., 2009; Slawek et al., 2008).  
3.6.4 Executive functions  
Executive functions were assessed in 10 studies and the most administered tests were the 
Stroop (n= 4 studies), the Frontal Assessment Battery (FAB) (n=4 studies) and the Trail 
Making Test (TMT) (n=2 studies). All other tests assessing executive functions were used 
only once (see Table 4).  
Ozer et al. (2006) found significant lower scores on the Stroop and Wisconsin Card Sorting 
Test (WCST) in PD with Hcy ≥14 μmol/L compared to PD with Hcy <14 μmol/L. However, 
4 studies registered no association between Hcy levels and executive functions: on the 
Stroop test (O’Suilleabhain et al. 2004; Rodriguez-Oroz et al., 2009), even after 2 years of 
follow-up (O’Suilleabhain et al., 2006); and on the TMT and the Raven Progressive Matrices 
(Hassin-Baer et al., 2006; Rodriguez-Oroz et al., 2009).  
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Slawek et al. (2008) found no association between the Tower of Toronto score and the 
presence of HT, DM, HCL, HD, smoking and alcohol intake. Haugarvoll et al. (2005), Levy 
et al. (2002) and Camicioli et al. (2009) didn’t report results on tests of executive functions in 
relation with VRF. 
3.6.5 Language  
Language was assessed in 10 studies and the most administered tests were verbal fluency 
tests (VFT; category and letter; n=7 studies) and the Boston Naming Test (BNT) (n=2 
studies). All other tests assessing language were used only once (see Table 4). 
In the R-DB-PC study of Barone et al. (2008), ŃHcy-rivastigmine-treated patients improved 
significantly on letter fluency after 24 weeks compared with ŃHcy–placebo-treated patients, 
and this improvement wasn’t present in the normal/low homocysteine groups. Moreover, 
O’Suilleabhain et al. (2004, 2006) found that PD patients with Hcy ≥14 μmol/L compared to 
those with Hcy <14 μmol/L had significantly lower score on verbal fluency at baseline, but 
the scores of the 2 groups were comparable at follow-up. However, other studies found no 
association between Hcy levels and scores of verbal fluency (Hassin-Baer et al., 2006; Ozer et 
al., 2006; Rodriguez-Oroz et al., 2009) and of the BNT (Rodriguez-Oroz et al., 2009).  
Verbal fluency scores were significantly associated with an increase of intimomedial 
thickness and of the pulsatility index (Rektor et al., 2009), as well as with coronary HD 
(Slawek et al, 2008).  
However, verbal fluency scores were not associated with presence of smoking, HT, DM, 
ischemic heart disease and stroke (Rektor et al., 2009). Levy et al. (2002) and Camicioli et al. 
(2009) didn’t report results on language tests.  
3.6.6 Attention and vigilance  
Attention and vigilance were assessed in 5 studies and the most administered test was Digit 
Span (n= 4) while the CDR Computerized Assessment System Power of Attention test 
(CDR-PoA) was only administered once. The R-DB-PC study of Barone et al. (2008) found 
that ŃHcy-rivastigmine-treated patients had a significant improvement on the CDR-PoA 
after 24 weeks compared to ŃHcy-placebo-treated patients, and this improvement wasn’t 
present in the rivastigmine and placebo-treated Hcy-normal groups.  
However, in other studies, PD with Hcy ≥14 μmol/L and PD with Hcy <14 μmol/L had 
comparable performances on Digit Span at baseline (Hassin-Baer et al., 2006; O’Suilleabhain 
et al., 2004; Rodriguez-Oroz et al., 2009;) and 2 years later (O’Suilleabhain et al., 2006). 
3.6.7 Visual perception  
Visual perception was assessed in 3 studies using the Benton Judgment of Line Orientation 
(BJLO) test (n=2 studies), the Benton Face Recognition (BFR) test (n=1 study) and the 
matching part of the Benton Visual Retention Test (BVRT) (n=1 study). 
Ozer et al., 2006 reported a significant negative correlation between the concentration of Hcy 
and the BFR. Results on the BVRT (Levy et al., 2002) and on the BJLO (Haugervoll et al., 
2005) were not reported.  
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Table 1. Study Design and Participant’s Characteristics (continued) 
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Legend: - (not applicable), ? (unknown or not clear), BL (Baseline), FU (Follow-Up);  
Design: BPC (Between Patients Comparisons), CC (Case-Control Study), CS (Cross-sectional Study), LON (Long
(Randomized Double-Blind Placebo-Controlled design), WPC (Within-Patient Comparisons);  
Participants: CD (Cognitive Decline), HC (Healthy Controls), CN (Cognitively Normal), CogI (Cognitive Impairmen
(Homocysteine= hyperhomocysteinemia), MCI (Mild Cognitive Impairment), no-VRF (No Vascular Risk Factors), PD
PDD (Parkinson’s disease with dementia), VRF (Vascular Risk Factors);  
Participants’ characteristics: COM (Community), H&Y (Hoehn and Yahr Stage), HOS (Hospitals), III-OFF (Sectio
the UPDRS), MC (Multicenter), MDC (Movement Disorder Center), MDD (Movement Disorder Database), M/F 
(Unified Parkinson’s Disease Rating Scale);  
PD diagnostic criteria: DSM-IV (Diagnostic and Statistical Manual of Mental Disorders - 4th edition), NINDS (Nat
Disorders and Stroke), UKPDSBRC (United Kingdom Parkinson’s Disease Society Brain Research Centre). 
Table 1. Study Design and Participant’s Characteristics (continued) 
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UKPDSBRC criteria 
(Gibb et al., 1988) 
NINDS criteria (Gelb et al., 1999) 
“Norwegian” criteria  
(Larsen et al., 1992) 
 
Step 1 - Diagnosis of Parkisonism
Bradykinesia 
At least one: muscular rigidity, 
4-6 Hz rest tremor, postural 
instability not caused by 
primary visual, vestibular or  
proprioceptive dysfunction. 
 
 
 
 
Step 2 - Exclusion criteria for PD 
History of repeated strokes 
with stepwise progression of 
parkinsonian features 
History of repeated head injury
History of definite encephalitis 
Oculogyric crises 
Neuroleptic treatment at onset 
of  symptoms 
More than one affected relative
Sustained remission 
Strictly unilateral features after 
3  years 
Supranuclear gaze palsy 
Cerebellar signs 
Early severe autonomic 
involvement 
Early severe dementia with 
disturbance of memory, 
language and praxis 
Babinski sign 
Presence of cerebral tumor or 
communicating hydrocephalus 
on CT scan 
Negative response to large 
doses of  levodopa (if 
malabsorption excluded) 
MPTP exposure 
 
 
 
Step 3 - Supportive prospective 
positive criteria for PD 
(3 or more required for diagnosis of 
definite IPD) 
 
Unilateral onset 
Rest tremor present 
Progressive disorder 
Persistent asymmetry affecting 
side  of onset most 
Grouping of clinical features of 
Parkinson’s disease according to 
diagnostic utility 
 
Group A: characteristic of PD 
- Resting tremor, Bradykinesia, 
Rigidity,Asymmetric onset 
 
Group B: suggestive of alternative 
diagnoses 
- Features unusual early in the  
clinical course: prominent 
postural  instability in the first 3 
years after  symptoms onset, 
freezing phenomena  in the first 
3 years, hallucinations unrelated 
to medications in the first 3  
years, dementia preceding 
motor symptoms or occurring in 
the first  year 
- Supranuclear gaze palsy (other  
than restriction of upward gaze) 
or slowing of vertical saccades 
- Severe, symptomatic 
dysautonomia unrelated to 
medications 
- Documentation of a condition  
known to produce parkinsonism 
and plausibly connected to the  
patient’s symptoms (such as 
suitably located focal brain 
lesions  or neuroleptic use 
within the past  6 months) 
 
1) Criteria for POSSIBLE diagnosis 
of PD 
At least 2 of the 3 features in Group 
A are present and at least 1 of these 
is tremor or bradykinesia. 
and 
Either none of the feature in Group 
B is present 
Or symptoms have been present for 
less than 3 years, and none of the 
features in Group B is present to date
and 
Either substantial and sustained 
response to levodopa or a 
dopamine agonist has been 
documented 
Or patients has not had an adequate 
trial of levodopa or dopamine 
agonist 
 
1) Criteria for POSSIBLE diagnosis 
of PD 
- Presence of at least two of the 
following signs: resting 
tremor, akinesia/ 
bradykinesia, rigidity,  
postural abnormality 
- Moderate response to 
dopamine agonist 
- At onset of disease absence of 
significant changes on CT or 
MRI other than diffuse 
cortical atrophy or mild 
hyperintense periventricular 
foci on MRI. Mild/moderate 
dementia and autonomic 
failure which still may be 
compatible with Parkinson’s 
disease. Absence of 
pyramidal and cerebellar 
signs, as well as 
environmental factors like 
drugs and toxic substances 
and a history of encephalitis 
that may cause a 
symptomatic parkinsonism. 
 
 
2) Criteria for PROBABLE 
diagnosis of PD 
Type A: Patients with bilateral 
onset of signs and who fulfill the 
following I, II and III criteria. 
 
Type B: Patients with unilateral 
onset and who fulfill criteria I, II 
and IV. 
 
Type C: Patients with unilateral 
onset and who fulfill criteria I, III 
and V. 
 
I. Presence of at least two of the 
following signs: resting tremor, 
akinesia/bradykinesia, 
rigidity, postural abnormality 
II. Good/excellent response to 
dopamine agonist. 
III. At onset of disease absence of 
significant changes on CT or 
MRI other than diffuse cortical 
atrophy or mild hyperintense 
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Excellent (70-100%) response to 
levodopa 
Severe levodopa-induced 
chorea 
Levodopa response for 5 years 
or  more 
Clinical course of 10 years or 
more 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2) Criteria for PROBABLE 
diagnosis of PD 
At least 3 of the 4 features in Group 
A are present 
and 
None of the features in Group B is 
present (symptom duration of at 
least 3 years is necessary to meet 
this requirement) 
and 
Substantial and sustained response 
to levodopa or a dopamine agonist 
has been documented 
 
 
3) Criteria for DEFINITE diagnosis 
of PD 
All criteria for POSSIBLE diagnosis 
of PD are met 
and 
Histopathologic confirmation of the 
diagnosis is obtained at autopsy 
 
Proposed criteria for 
Histopathologic confirmation of 
Parkinson Disease 
- Substantial nerve cell depletion 
with accompanying gliosis in 
the substantia nigra 
- At least 1 Lewy body in the 
substantia nigra or in the locus 
coeruleus (note: it may be 
necessary to examine up to 4 
non-overlapping sections in 
each of these areas before 
concluding that Lewy bodies are 
absent) 
- No pathological evidence for 
other diseases that produce 
Parkinsonism (eg progressive 
supranuclear palsy, multiple 
system atrophy, cortical–basal 
ganglionic degeneration) (Note: 
in excluding other diseases that 
produce Parkinsonism, 
published consensus criteria 
should be used when available) 
periventricular foci on MRI. 
Absence of clinical exclusion 
criteria like dementia, 
pyramidal and cerebellar signs 
and autonomic failure which 
may indicate another 
neurodegenerative disorder. 
Absence of environmental 
factors like drugs and toxic 
substances and a history of 
encephalitis  that may cause a 
symptomatic parkinsonism. 
IV. Unilateral onset of symptoms 
and asymmetrical 
development of disease. 
Presence of mild dementia or 
autonomic failure. Otherwise, 
as in III. 
V. Unilateral onset of symptoms 
and asymmetrical 
development of disease. 
Moderate response to 
dopamine agonist. 
 
3) Criteria for DEFINITE diagnosis 
of PD 
- Presence of resting tremor and 
at least two of the following 
signs: akinesia/bradykinesia, 
rigidity,postural abnormality 
- Unilateral onset of signs and 
asymmetrical development of 
the disease. 
- Good/excellent response to 
dopamine agonist. 
- At onset of disease absence of 
significant changes on CT or 
MRI other than mild diffuse 
cortical atrophy or mild 
hyperintense periventricular 
foci on MRI. Absence of clinical 
exclusion criteria like dementia, 
pyramidal and cerebellar signs 
and autonomic failure which 
may indicate another 
neurodegenerative disorder. 
Absence of environmental 
factors like drugs and toxic 
substances and a history of 
encephalitis that may cause a 
symptomatic parkinsonism. 
 
Table 2. The Diagnostic Criteria for PD 
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Legend: - (not applicable), ? (unknown or not clear); Vascular risk factors (VRF): ŃHcy (Hyperhomocysteinemia), 
Diabetes Mellitus), HCL (Hypercholesterolemia), HD (Heart Disease), HT (Hypertension), SMO (Smoking), HS/T
Ischemic Attacks); VRF measures: Hcy (Low/normal Level of Homocysteine), CCA-IMT (Common Carotid Ar
(Homocysteine), MRI (Magnetic Resonance Imaging), PI (Pulsatility Index), RI (Resistance Index), WMH (White M
Medication: Anti-ACh (Anticholinergics), DAA (Dopamine Agonist), L-dopa (levodopa); Groups: PD (Parkinson
disease-Cognitively Normal), PDD (Parkinson’s disease with Dementia), PD-MCI (Parkinson’s disease with Mild
Table 3. Vascular Risk Factors and their Measurements 
w
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w
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? =unknown or unclear /NS = Not Significant  
Legend: Ń (Increase), ↔ (Association), ADAS-Cog ( Alzheimer’s Disease Assessment Scale- Cognition), ADCS-ADL (A
Study-Activities of Daily Living), ADCS-CGIC (Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression o
Scale), BFR (Benton Face Recognition), BJLO (Benton Judgment of Line Orientation), BL (Baseline), BNT (Boston Naming
Orientation Test), BVRT (Benton Visual Retention Test), CCA-IMT (Common Carotid Artery Intima-Media Thickness), CD
(Cognitive Drug Research), CDT (Clock Drawing Test), CI (Confidence Interval), CogI (Cognitive Impairment), COWA
Association Test), CRT (Choice Reaction Time), DA (Dopamine), D-KEFS (Delis-Kaplan Executive Fonction System), D
(Dementia Rating Scale), dx (Diagnosis), EBMT (East Boston Memory Test), FAB (Frontal Assessment Battery), FCSRT (F
Test of Buschke), FU (Follow-up), GBS (Gottfried-Brane-Steen scale), GDS (Geriatric Depression Scale), H & Y (Hoehn an
HT (hypertension), HVLT (Hopkins Verbal Learning Test), IADL (Instrumental Activities of Daily Living), ITT-RDO (I
out), LOCF (Last Observation Carried Forward), MC (Multiple Centers), MMSE (Mini-Mental State Examination), nHc
VRF (No Vascular Risk Factors), NPI (Neuropsychiatric Inventory), NSAID (Nonsteroidal Anti-Inflammatory Drug), O
Ratio), PD-CN(Parkinson’s Disease – Cognitively Normal), PDD (Parkinson’s Disease with Dementia), PD-MCI (Parkins
Impairment), PDnD (Parkinson’s disease, no dementia), PoA (Power of Attention tests), PI (Pulsatility Index), RAVLT (Rey
Test), RI (Resistance Index), ROCF (Rey-Osterrieth Complex Figure), RR (Risk Ratio), S&E (Schwab and England score), S
STMS (Short Test of Mental Status), sx (Symptoms), TMT (Trail Making Test), UPDRS (Unified Parkinson’s Disease rat
Task), VRF (Vascular Risk Factors), WBIS (Wechsler-Bellevue Intelligence Scale), WMH (White Matter Hyperintensities
Scale, 3rd version), WCST (Wisconsin Card Sorting Test), WMH (White Matter Hyperintensities), WS (Wahlund Scale).
Table 4. Cognitive Measures, Cognitive Results and Other Key Results 
w
w
w
.intechopen.com
 Idiopathic Parkinson’s Disease, Vascular Risk Factors and Cognition: A Critical Review 
 
347 
3.6.8 Construction praxis  
Construction praxis was assessed in 4 studies using the Clock Drawing Test (CDT) (n=3 
studies), the Block Design of the Wechsler Adult Intelligence Scale 3rd edition (WAIS-III) and 
the copy part of the ROCF. Only 1/4 studies reported a significant association between the 
presence of VRF and a decline in the construction praxis. O’Suilleabhain et al. (2004; 2006) 
found a significantly worse performance on Block Design (WAIS-III) and on ROCF-copy in 
the PD group with Hcy>14 μmol/L compared to PD with Hcy < 14 μmol/L at baseline, but 
not at 2-year follow-up.  
Ozer et al. (2006) didn’t find significant differences on the CDT score between PD ≥14 
μmol/L, PD <14 μmol/L and healthy controls. Camicioli et al. (2009) didn’t report results of 
specific analyses concerning the CDT.  In addition, CDT was significantly associated with an 
increase of intimomedial thickness and of the pulsatility index, but not with the presence of 
smoking, HT, DM, ischemic HD and stroke (Rektor et al., 2009). 
3.6.9 Orientation  
Orientation was assessed in 2 studies using the Benton Temporal Orientation Test (BTOT) (1 
study) and some MMSE items (1 study). Positive correlations between the BTOT and the 
increase of intimomedial thickness, the pulsatility index and the resistance index were 
found, but there was no correlation with smoking, HT, DM, ischemic HD and stroke (Rektor 
et al., 2009). Levy et al. (2002) didn’t report results on the MMSE-orientation items.  
3.6.10 Speed of information processing  
Speed of information processing was assessed in only one study with the Choice Reaction 
Time (CRT) test. The R-DB-PC study of Barone et al. (2008) found that ŃHcy patients treated 
with rivastigmine had a significant improvement on the CRT after 24 weeks compared to 
ŃHcy-placebo-treated patients, and this improvement wasn’t present in the < 14 μmol/L 
group.  
4. Conclusion 
The main objective of this review was to determine whether there is a relationship between 
VRF and cognition in PD or not. Consequently, a thorough search in several relevant 
databases was conducted, and 18 studies were found. After a comprehensive analysis of the 
articles content, a relationship was evidenced between cognition and Hcy, but the link 
between heart disease, smoking and cognition was more controversial. There was no 
evidence of any relationship between cognition and diabetes mellitus, hypertension, alcohol 
intake, stroke history/transient ischemic attack and hypercholesterolemia.  
4.1 Homocysteine and cognition 
Hyperhomocysteinemia in PD was associated with worse cognition and/or dementia in 6/9 
studies of this review; 3/9 studies found no association. This finding is partly supported by 
the results of a previous review of 16 articles by Zoccolella et al. (2010) who reported 
significant associations in 9 publications investigating cognition or dementia in relationship 
with ŃHcy. Nine out of 16 studies of Zoccolella and colleagues overlapped some articles 
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included in the current review. However, the inclusion criteria of the current review were 
more rigorous, and excluded published abstracts of conference presentations. Furthermore, 
the current review also collected more demographic and clinical data on PD patients and 
controls, and reported results in a more detailed fashion, hence allowing easier comparisons 
and exploration of possible interactions or co-occurrence between VRF. Nevertheless, the 
relationship between cognition/dementia and ŃHcy remained relatively consistent. 
Some of the divergent findings in the global cognitive outcomes of the 9 studies that 
investigated Hcy may be explained by several factors. For instance, in all these studies, those 
with greater sample size and using a longitudinal design were more likely to find a 
significant association compared to the studies that didn’t find a significant association. In 
brief, studies that found significant associations possibly presented a more robust design, 
greater statistical power and also possibly a higher dosage of L-dopa. Among the 3 studies 
that didn’t find an association with Hcy and cognition, one didn’t clearly report medication 
dosages. Other possible explanations involve the use of different technologies to measure 
Hcy levels (high performance liquid chromatography with fluorescence detection, 
fluorescence polarization immunoassay, chemiluminescent enzyme immunoassay) and the 
measurement of Hcy levels under different fasting conditions (food and drugs). 
Interestingly, the Hcy studies demonstrated that Hcy may affect episodic memory 
(O’Suilleabhain et al., 2004, 2006; Ozer et al., 2006), executive functions (Ozer et al., 2006), 
language (Barone et al., 2008; O’Suilleabhain et al., 2004, 2006), attention/vigilance (Barone 
et al., 2008), construction praxis (O’Suilleabhain et al., 2004, 2006) and speed of information 
processing (Barone et al., 2008). This could reflect a vascular contribution to cognitive 
impairment since executive functions, attention and some aspects of episodic memory are 
linked to frontal-subcortical loops (Sachdev et al., 2005). Indeed similar results were found 
in studies performed in elderly with VRF, some even found poorer performance with Hcy 
for specific cognitive domains like episodic memory (Morris et al., 2001), executive functions 
(Duthie et al., 2002) and attention (Duthie et al., 2002). However, this cognitive profile is 
prominently found in PD patients with cognitive impairment (without VRF), since the 
alteration of the frontal-striatal system could cause a similar executive dysfunction 
(Zgaljardic et al., 2003). Hence, it could be hypothesized that: 1) ŃHcy amplifies the severity 
of the executive impairment already present in PD patients; and/or 2) that ŃHcy increases 
the susceptibility of some cerebral regions to vascular impairment (i.e. ischemic lesions in 
these specific regions); and/or 3) that ŃHcy accelerates the neurodegenerative process of PD 
in some aspects, because of its acknowledged neurotoxicity (Sachdev, 2005). Nonetheless, 
further research is required to clarify these hypotheses. 
4.1.1 What could explain the link between Hcy and cognition?  
Elevated Hcy is associated with brain atrophy by several vascular mechanisms (for a review 
on the question, see Sachdev, 2005) such as promoting endothelial cell injury (formation of 
atherosclerosis in the blood vessel walls and reduced thrombo-resistance), increasing 
platelet aggregation (by increasing thromboxane A2 synthesis and decreasing postacyclin), 
affecting factors of the clotting cycle (and inhibition of the natural anticoagulants), and 
favors the adhesion of platelets to the endothelium. Hence, these results may support a 
possible vascular contribution to cognitive impairment by Hcy. As mentioned in section 
3.4.1, L-dopa intake in PD patients induces increased levels of Hcy (Kuhn et al., 1998; Müller 
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et al., 1999; Rogers et al., 2003; Yasui et al., 2000) because L-dopa breakdown interferes with 
Hcy metabolism. Since Hcy also has been associated with hypertrophy of the intima-media 
complex of the carotid artery, a marker of atherosclerotic disease (Megnien et al., 1998), L-
dopa-induced ŃHcy may promote systemic atherosclerosis processes, thus compromising 
vascular health. This is supported by the findings of Nakaso et al. (2003) who reported that 
patients treated with L-dopa for longer duration had increased hypertrophic changes in the 
intima-media complex of the carotid artery, and that ŃHcy promoted by both longer L-dopa 
treatment and MTHFR T/T genotype may amplify atherosclerotic processes.  
4.1.2 Neurotoxicity of homocysteine 
In the current review, the study conducted by Barone et al. (2008) brought indirect support 
for a neurotoxic effect of Hcy on brains cells. As mentioned above, Hcy causes increased 
oxidative stress, excitotoxicity, promotes cellular apoptosis and accumulation of amyloid ǃ-
peptide and abnormal tau phosphorylation. The brain is particularly vulnerable to Hcy, 
because it lacks two major Hcy metabolic pathways (via methionine synthase and via 
cystathionine-ǃ-synthase)(Finkelstein, 1998). The R-DB-PC study of Barone et al. (2008) 
successfully demonstrated that global cognitive function, verbal fluency, attention, and 
speed of information processing of hyperhomocysteinemic PD patients benefited from 
rivastigmine treatment. These results may support the hypothesis of the contribution of a 
cholinergic system imbalance in cognitive impairment and dementia in PD. Indeed, 
rivastigmine inhibits acetycholinesterase (AChE) and butyrylcholinestersase (BuChE) 
(Darreh-Shori et al., 2002), two enzymes that catalyze the hydrolysis of acetylcholine (ACh) 
in neurons (Lane et al., 2006). Hyperhomocysteinemia could be deleterious to the ACh 
system of PDD because a metabolite of homocysteine (homocysteine thiolactone) is known to 
increase the enzymatic activity of BuChe (Darvesh et al., 2007). Since the BuChE highest 
activity is reported in deep gray and white matter brain regions, hyperhomocysteinemia 
may be linked to subcortical atrophy and white matter lesions (Darvesh et al., 2007; Sachdev 
et al., 2005). Apart from the compensation for ACh deficiencies, another hypothesis for the 
benefit of rivastigmine treatment could be that rivastigmine may reduce inflammation and 
oxidative stress in neurons (Schulz et al., 2002; Tanaka et al., 1995). These pathological 
phenomena are promoted by ŃHcy (Sachdev et al., 2005) and could be involved in PDD. 
Nevertheless, the underlying mechanisms of rivastigmine treatment effects on cognition in 
hyperhomocysteinemic patients are still hypothetical (Barone et al., 2008).  
4.2 Smoking and cognition in PD 
The question of whether smoking is a protective factor for PD or a factor promoting 
cognitive impairment and dementia is very controversial. A significant relationship between 
cognition and smoking in PD was found in 3/8 studies of this review: a higher risk for 
dementia in current smokers (Levy et al., 2006), and a worse performance on a global 
cognitive measure in patients with history of smoking (indirectly in Matteau et al., 2010; and 
directly in Weisskopf et al., 2007). Nevertheless, the data extracted from the 8 articles were 
conflicting since 5/8 studies didn’t find a significant association between cognition and 
smoking in PD. However, most of these 5 studies only reported smoking as present or not in 
the sample. Consequently, comprehensive analyses between different smoking status and 
cognitive results were not conducted. In fact, Haugarvoll et al. (2005), Rektor et al. (2009) 
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and Slawek et al. (2008) didn’t report results specific to smoking. Moreover, the number of 
PD smokers in the samples was very small, thus making it difficult to draw any conclusion 
on the definitive impact of smoking on cognition in PD. It could be argued that studies that 
found significant associations had a larger sample size of smokers and thus more statistical 
power. In addition, when specified, the number of current smokers compared to past 
smokers was relatively small. Although some studies assessed smoking in a more detailed 
fashion, cognition was only assessed with brief global measures that could potentially mask 
effects on specific cognitive domains. Hence, it is justified to doubt if cognitive deficits, 
when found in association with smoking, were present at the time of diagnosis or reflected a 
faster decline after PD onset. Nevertheless, an early study evaluating the risk of dementia in 
PD smokers compared to non smokers (Ebmeier et al., 1990) found that the odds ratio for 
dementia in smokers was 4.0 (95% CI:1.4 –12.0) compared to non smokers, which clearly 
indicates a risk for cognitive deterioration in PD smokers.  
The controversy regarding the association between smoking and greater cognitive decline in 
PD patients stems from the fact that tobacco use has been quite consistently reported as a 
dose-dependent protective factor for PD development in several studies as evidenced in the 
pooled analysis of Ritz et al. (2007). Although the current review couldn’t draw definitive 
conclusions on smoking as a VRF for cognitive decline in PD, some hypotheses can be made 
over the conflicting results. Animal studies hypothesized that nicotine delivered through 
cigarette smoke may exert a protective effect on dopaminergic (DA) neurons in the 
substantia nigra, thus enhancing the survival rate of animals. In fact, Parain et al. (2003) 
examined the effects of cigarette smoke and nicotine in an animal model of PD provoked by 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication in mice. They found that 
the loss of DA neurons in the substantia nigra was significantly less severe in the group 
treated with injections of nicotine and in the group with low exposure to cigarette smoke, 
compared to the groups treated with placebo and highly exposed to cigarette smoke.  
Moreover, the study of Park et al. (2007) with microglia cultures demonstrated that nicotine 
had a neuroprotective effect on DA neurons due to an anti-inflammatory action. Supporting 
the results of animal studies, Kelton et al. (2000) reported improvements in reaction time, 
central processing speed and tracking in 15 non-demented PD patients after they received 
an acute administration of nicotine (phase I). Several motor measures also improved after 
chronic administration of nicotine patches (phase II), thus reinforcing the aforementioned 
hypothesis. This is particularly interesting for PD, since alterations of the nicotinic binding 
sites in the pars compacta of the substantia nigra were associated with PD (as well as in AD 
and in Lewy body disease) (Perry et al., 1995). In fact, abnormalities of the nicotinic 
receptors may precede DA neurodegeneration. 
On the other side, while nicotine may protect against nigral neuronal losses, side effects 
from the other compounds of cigarette smoke may be deleterious for the vascular system 
and for brain cells health even in non PD elderly. A diminution of gray matter density in the 
posterior cingulate cortex, the precuneus, the right thalamus and the frontal cortex were 
found in elderly smokers (otherwise healthy) compared to non-smokers. These cerebral 
regions are associated with incipient AD (Almeida et al., 2008). Some neuroimaging studies 
associated smoking with increased cerebral infarcts, white matter hyperintensities, 
subcortial atrophies and elevated amyloid plaques (Swan & Lessov-Schlaggar, 2007; Tyas et 
al., 2003). Furthermore, some studies conducted in non-demented elderly reported that 
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smoking increased difficulties in psychomotor and information processing speed (Hill, 1989; 
Kalmijn et al., 2002), verbal learning, cognitive flexibility (Kalmijn et al., 2002), distracters 
inhibition and global executive functions (Paul et al., 2006; Razani et al., 2004). However, 
some authors didn’t find any deleterious effect of smoking on cognitive measures (Schinka 
et al., 2002). These findings highlight the controversy regarding the impact of cigarette 
smoking on cognition. Nonetheless, the results of the current review cannot draw a specific 
cognitive profile in PD associated with smoking as a VRF, because significant effects were 
only reported on global cognitive measures. In fact it is possible that cigarette smoking — 
especially nicotine in cigarette smoke — could affect PD brains differently than healthy 
elderly, probably because of PD-related changes.  
4.3 Heart disease and cognition in PD 
The data of the current review associated the presence of HD in PD with dementia 
(Haugarvoll et al., 2005; Slawek et al., 2008), and impairment in episodic memory and 
language (Slawerk et al., 2008). However, these associations were weak and controversial, 
since another study did not report any association (Rektor et al., 2009). Yet the association 
between HD and cognition in PD is at least partly supported by the literature in non-PD 
elderly. For instance, Ylikoski et al. (2000) reported that non-PD elderly with heart failure 
and showing white matter changes and central atrophy had significantly worse cognitive 
performance in tests measuring visuoconstruction, attention and cognitive flexibility 
compared to healthy individuals. Interestingly, several studies strongly associated Hcy 
with a higher risk of HD in healthy individuals. For instance, a meta-analysis by Wald et al. 
(2002) evidenced a causal relationship between Hcy levels and ischemic HD and found that 
lowering Hcy levels from current level by 3μmol/L could reduce the risk of ischemic HD by 
11% to 20%. Nonetheless, none of the articles investigating Hcy in this review reported the 
cardiac health condition of the ŃHcy patients and none of the studies reporting heart 
diseases assessed Hcy levels, so this relationship wasn’t reported in the 9 articles. 
4.4 Diabetes mellitus, hypertension, hypercholesterolemia, alcohol and cognition in 
PD 
None of the studies of this review reported a significant association between DM, HT and 
HCL and cognition in PD. However, in most cases, these VRF were considered only as 
secondary variables and the potential relations with cognition were not always thoroughly 
assessed. In addition, these results don’t reflect those obtained in non-PD populations, 
because several studies associated type 2 DM with cognitive impairment. A literature 
review showed that type 2 DM is cross-sectionally associated with cognitive impairment in 
healthy elderly and is considered as a risk factor for both vascular dementia and AD in 
several studies (Stewart & Liolitsa, 1999). Moreover, higher risk of poor performance on 
verbal episodic memory and concept formation with longer DM duration was demonstrated 
in a large prospective cohort of non-PD individuals with DM followed during nearly 30 
years (Elias et al., 1997).  
A possible explanation for the difficulty to draw specific conclusions regarding the presence 
of HT, DM and HCL in PD and their impact on cognition could be that some studies found 
inverse associations with these VRF and the risk for PD. In fact, a significant inverse 
relation/lower odds ratio for PD was shown in individuals with HT (Herishanu et al., 2001; 
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Miyake et al., 2010; Scigliano et al., 2006), DM (Herishanu et al., 2001; Miyake et al., 2010; 
Scigliano et al., 2006) and HCL (Miyake et al., 2010 Scigliano et al., 2006). The study of 
Scigliano et al. (2006) suggested that the reduced risk for vascular disorders in untreated PD 
patients could stem from a reduced autonomic activity in PD. While sympathetic 
hyperactivity is known to exacerbate high blood pressure, diabetes and dyslipidemia, PD 
patients present with cardiac sympathetic denervation and parasympathetic dysfunction 
(Buob et al., 2010; Shibata et al., 2009), thus possibly reducing HT and other VRF related to 
it. In addition, the reduction in sympathetic activity may be relevant for postural 
hypotension reported in 70% of PD patients (Appenzeller & Goss, 1971; Shindo et al., 2003).  
The fact that patients were untreated in the study of Scigliano et al. (2006) could be a key 
factor since L-dopa-treated patients are more susceptible to have higher Hcy levels (see 
section 3.4.1), they are also at an increased risk for cerebrovascular and cardiovascular 
disorders. Yet, Jellinger (2003) found that the frequency of brain lesions associated with 
vascular disease such as white matter lesions, ischemic infarcts, hemorraghes and lacunes, 
was higher in PD patients compared to controls, but more severe ischemic and hemorrhagic 
strokes often leading to death were less frequent in PD patients. The findings of Jellinger 
thus mitigate the impact of cerebrovascular lesions in PD patients. 
4.5 Limitations of the reviewed articles 
The studies included in the review presented several limitations. There was a small number 
of studies for some VRF such as DM, HCL, HT, HD, SH/TIA and as a consequence, there 
was a lack of analyses on these variables in link with cognitive measures. For instance, 
although HT didn’t seem associated with cognition in 6/9 studies, 3/9 did not report if 
there was any association or not, thus suggesting that these analyses were not even realized, 
probably because these VRF weren’t the main focus in these studies. Moreover, it is rather 
difficult to draw a conclusion regarding the impact of some VRF such as SH, TIA, alcohol 
intake and HCL because only a few studies assessed their links with cognition. As explained 
previously, PD patients are less susceptible than controls to be diagnosed with HT, DM and 
HCL, thus making it difficult to perform a comprehensive assessment of the relation 
between these VRF, cognitive impairment and PDD. 
The cross-sectional design of the studies could also have influenced the cognitive profile of 
PD patients with and without VRF. For instance, two studies with a longitudinal component 
(Barone et al.,2004; O’Suilleabhain et al., 2004; 2006) found a significant association with 
elevated Hcy and worse cognitive performance, but inconsistencies were found in the case-
control studies. Thus, an important limitation of the review data concerns the lack of 
longitudinal and cohort studies on most VRF.  
While most studies used comparable diagnostic criteria (see Table 2), a considerable number 
of studies reported severe exclusion criteria for PD participants, such as the exclusion of 
cognitively impaired or demented patients (see Table 1). Since demented and cognitively 
impaired PD patients were systematically excluded in 7 studies, it is possible that an 
association between VRF and cognition was missed in these particular studies.  
Several studies (n=11) didn’t report education levels of the participants, and this may have 
had an impact on cognitive evaluation. Education is an important variable to consider when 
cognition is assessed because it is strongly correlated with cognitive performance on 
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neuropsychological tests, and this is the reason why good standardized cognitive tests are 
normalized according to age and education (Lezak et al., 2004). For the reasons stated above, 
it is delicate to compare results of patients with low-levels of education with those of 
patients with higher levels of education as Weisskopf et al. (2007) and Rodriguez-Oroz et al. 
(2009) did in their respective study.  
Only a few studies reported the use of magnetic resonance imaging (MRI) to correlate the 
cognitive deficits with objective brain changes and lesions. Apart from plasma measures of 
Hcy, the only biological measures used in the 18 articles that could without a doubt confirm 
a vascular disease or impairment were the measures of intimomedial thickness of the 
common carotid artery, as well as the pulsatility and resistance index in the studies of 
Rektor et al. (2009) and Hassin-Baer et al. (2006).  
Another important point to consider is the fact that the treatment of vascular conditions 
such as HT with antihypertensive medications could have mitigate the effects of some VRF, 
thus creating some kind of “false” at risk groups. It is particularly hard to estimate the 
consequences of such an effect, because most studies only reported PD-related drugs, and 
not the VRF treatment. Conversely, some medications such as beta-blockers, administered to 
control HT, are known to have deleterious effects on cognition (Gliebus and Lippa, 2007). 
Unfortunately this is also true for benzodiazepines (Kleykamp et al., 2010) often prescribed 
in PD as a muscle relaxant. Therefore it would be a good idea in the future to include 
information regarding medications in studies investigating the relationship between VRF 
and cognition in PD.  
Finally, the current review had specific inclusion criteria for the articles and thus, studies 
that didn’t report cognitive measures were not selected. However, other kinds of studies 
may bring some support to the effect of vascular disease and VRF on the clinical course of 
PD. For instance, Papapetropoulos et al. (2004) studied the impact of HT, DM, ischemic HD 
and stroke in late-onset PD patients and found that H&Y stages were significantly higher in 
patients with stroke, ischemic HD and DM compared to those without those VRF, thus 
suggesting some impact of VRF on disease severity and mechanisms.  
4.6 Recommendations for future studies 
Considering the outcomes of this review, some recommendations to improve research in 
this area can be formulated. Since the current review showed important inconsistencies in 
the neuropsychological assessment of PD patients, the development of a standardized and 
comprehensive assessment of cognition especially adapted for PD is mandatory. In fact, 
apart from the study of Weisskopf et al. (2007) that reported no changes in cognitive results 
after removing the results of one test that could be affected by bradykinesia, no study 
mentioned the use of motor controls for the neuropsychological assessment. Although some 
tests didn’t have a motor component, others, such as the CDT and ROCF, did. Since motor 
impairment is a prominent feature of PD, obtaining pure cognitive measures can be 
challenging in tests requiring motor manipulations.  
In addition, studies assessing the impact of the interaction of several VRF (such as Hcy and 
HD; Hcy and smoking) on cognition should also be performed as well as studies 
comparing the VRF and cognitive functions in de novo untreated patients versus patients 
treated with L-dopa (e.g. for 5, 10 and 15 years). In all these studies, structural and 
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functional imaging data shall be provided in order to perform correlations with the 
cognitive and clinical measurements.  
Finally, future studies shall investigate indirectly the role of VRF in cognition by evaluating 
the impact of some VRF treatment like nicotine patch or antihypertensive/anti-HCL 
medication on the cognitive functions in PD patients.  
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